Andrew Dauber

The George Washington University School of Medicine and Health SCiences
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Introduction: Short stature is a common clinical feature of Turner syndrome (TS) and Noonan syndrome (NS). Growth hormone (GH) treatment increases height in patients with TS and NS. We aimed to assess treatment patterns and costs in a real-world setting of GH-treated patients with TS and NS in the USA. Methods: Patients with TS (aged 4 to <14 years) or NS (aged ≤18 years) were included in this retrospective analysis using the Komodo Health claims database. The study period from January 1, 2016, to September 30, 2022, included ≥6 months pre-index (baseline) and ≥1 year post-index (follow-up); the index date was the first (TS) or latest of two visits (NS) with diagnostic coding for the condition. Data were analyzed descriptively. Results: Among 2,530 patients with TS (mean age [SD] 8.4 [3.0] years) and 1,119 patients with NS (mean age 7.0 [4.4] years), 36% and 16% initiated GH treatment during follow-up, respectively. Of these patients, 48%/41% were early initiators (started ≤6 months post-index), 66%/70% had high adherence (≥80% of GH treatment days covered), and 56%/52% had long persistence (treated ≥2 years). Mean GH treatment duration was 24.9 (15.9) and 17.6 (10.1) months for patients with TS and NS, respectively. Median (IQR) total all-cause costs per patient/year were USD 10,232 (USD 2,850–USD 36,590) and USD 17,937 (USD 5,616–USD 47,552), respectively. Conclusion: Of the few patients on GH therapy, less than half were initiated on treatment early after their TS or NS diagnosis. Greater awareness regarding early diagnosis and treatment of TS and NS is needed.

Year:

2025

Introduction: Vosoritide is a C-type natriuretic peptide (CNP) analog that binds its receptor on chondrocytes, promoting growth by inhibiting the ERK1/2-MAPK pathway. We previously reported the results of a phase II study in children with hypochondroplasia. Vosoritide led to an average increase in annualized height velocity (AHV) of 1.81 cm/year and gain of 0.36 in height standard deviation (SD) over 12 months. We present here the pharmacokinetic/pharmacodynamic (PK/PD) data from this study and examine the correlations between these parameters and growth outcomes. Methods: We conducted a phase II trial of daily subcutaneous vosoritide (15 μg/kg/day) in 24 prepubertal subjects with hypochondroplasia (12 females, mean age 5.9 ± 2.3 years, mean height −3.29 + 0.68 SD). Plasma vosoritide levels were assayed using an electrochemiluminescence assay. PD markers including serum collagen X biomarker (CXM) and urine cyclic guanosine monophosphate (cGMP) production were measured at day 1, month 6, and month 12 visits. Pearson correlations and regression analyses were performed between PK and PD parameters and growth outcomes. Results: Vosoritide PK parameters were similar to those previously reported in patients with achondroplasia. CXM levels increased from a baseline mean of 22.5 ± 6.5 to 41.6 ± 15.9 ng/mL after 12 months of treatment (p < 0.0001). Urine cGMP increased within 1 h and peaked at 2 h after injection. The mean AUC for cGMP production was not significantly different at each study visit. The maximum change in cGMP AUC correlated with PK AUC (r = 0.46, p = 0.0001). However, drug exposure, as measured by average PK AUC, did not correlate with any growth outcome. CXM levels correlated with the prior 6-month interval height velocity (partial correlation coefficient = 0.40, p = 0.0048). However, change in CXM did not correlate with change in height velocity or change in height SD during treatment. Conclusions: Vosoritide treatment showed improvement in AHV and height SD in children with hypochondroplasia. PK analysis indicates that drug exposure was correlated to global CNP activity as measured by urine cGMP but did not correlate with growth outcomes. More studies are needed to identify specific patient characteristics that can predict response to therapy and clinical outcomes.

Year:

2024

Context Patients with aggrecan (ACAN) deficiency present with dominantly inherited short stature, as well as early-onset joint disease. Objective The objective of this study was to evaluate the efficacy and safety of recombinant human GH (rhGH) on linear growth in ACAN-deficient children. Methods Open-label, single-arm, prospective study over 3 years recruiting 10 treatment-naïve patients with heterozygous mutations in ACAN, age ≥2 years, prepubertal, and normal IGF-I concentration. Patients were treated with rhGH (initially, 50 mcg/kg/day). Main outcomes were change in (Δ) height SD score (HtSDS) and height velocity (HV). Results Ten patients (6 females) enrolled with median chronological age (CA) of 5.6 years (range, 2.4-9.7). Baseline median HtSDS, HV, and bone age/CA were −2.5 (range, −4.3 to −1.1), 5.2 cm/year (range, 3.8 to 7.1), and 1.2 (range, 0.9 to 1.5), respectively. The cumulative median ΔHtSDS over 3 years was +1.21 (range, +0.82 to +1.94). Median HV increased to 8.3 cm/year (range, 7.3-11.2), 7.7 cm/year (range, 5.9-8.8), and 6.8 cm/year (range, 4.9-8.6) during years 1, 2, and 3, respectively. The median Δ predicated adult height was +6.8 cm over 3 years. Four female subjects entered puberty; nevertheless, median Δbone age/CA was −0.1. No adverse events related to rhGH were observed. Conclusion Linear growth improved in a cohort of ACAN-deficient patients treated with rhGH, albeit somewhat attenuated in older participants who entered puberty. Longitudinal follow-up is needed to assess the long-term efficacy of rhGH and adult height outcome.

Year:

2024

Context Rare patients with short stature and growth hormone (GH) resistance have dominant-negative variants in the GH receptor. We describe a patient with GH resistance due to elevated levels of GH binding protein and demonstrate the potential for a precision medicine intervention. Objective To determine whether high-dose GH can overcome GH resistance in this specific patient resulting in normal insulin-like growth factor (IGF)-1 levels and improved growth rates. Methods Single patient trial of ascending doses of GH followed by a dose stable phase: total 12 months of treatment. The patient has a heterozygous variant in the GH receptor resulting in elevated levels of GH binding protein manifesting as GH resistance and severe short stature. Daily subcutaneous GH was administered, starting at 50 µg/kg/day and escalating to 250 µg/kg/day until goal IGF-1 achieved. The subject continued on 250 µg/kg/day for a total treatment duration of 12 months. The primary outcome measure was the dose of GH required to achieve an IGF-1 level above the midpoint of the normal range. Secondary endpoints included height velocity and the change in height SDS during the first year of treatment. Results A dose of GH of 250 µg/kg/day achieved the target IGF-1 level. The patient's annualized height velocity was 8.7 cm/year, an increase of 3.4 cm/year from baseline, resulting in a 0.81 SD gain in height. Conclusion A precision medicine approach of extremely high dose GH was able to overcome GH resistance in a patient with a dominant-negative variant in the GH receptor resulting in elevated GH binding protein levels.

Year:

2024

Neurodevelopmental proteasomopathies represent a distinctive category of neurodevelopmental disorders (NDD) characterized by genetic variations within the 26S proteasome, a protein complex governing eukaryotic cellular protein homeostasis. In our comprehensive study, we identified 23 unique variants in PSMC5 , which encodes the AAA-ATPase proteasome subunit PSMC5/Rpt6, causing syndromic NDD in 38 unrelated individuals. Overexpression of PSMC5 variants altered human hippocampal neuron morphology, while PSMC5 knockdown led to impaired reversal learning in flies and loss of excitatory synapses in rat hippocampal neurons. PSMC5 loss-of-function resulted in abnormal protein aggregation, profoundly impacting innate immune signaling, mitophagy rates, and lipid metabolism in affected individuals. Importantly, targeting key components of the integrated stress response, such as PKR and GCN2 kinases, ameliorated immune dysregulations in cells from affected individuals. These findings significantly advance our understanding of the molecular mechanisms underlying neurodevelopmental proteasomopathies, provide links to research in neurodegenerative diseases, and open up potential therapeutic avenues.

Year:

2024

Year:

2023

Collaborators (33)

Ype Elgersma

Full professor

Erasmus MC

NETHERLANDS
View details

Tamar Harel

-

ISRAEL
View details

Geeske van Woerden

Associate professor

Erasmus University Rotterdam

NETHERLANDS
View details

Gajanthan Muthuvel

Assistant Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Rebecca Ganetzky

Associate Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

EFTERPI PAVLIDOU

Assistant Professor of Pediatrics

University of Ioannina

GREECE
View details

Peter Krawitz

University of Bonn

GERMANY
View details

Dominique Bonneau

Professor of Medical Genetics

Université d'Angers

FRANCE
View details

Arnaud Droit

Professor

Université Laval Faculté de médecine

CANADA
View details

Roopa Kanakatti Shankar

Children's National Health System

UNITED STATES
View details

Tzung-Chien Hsieh

University Hospital Bonn

GERMANY
View details

Evan Eichler

Howard Hughes Medical Institute

UNITED STATES
View details

Marie-Pierre Bousquet

Institute of Pharmacology and Structural Biology

FRANCE
View details

Peter Werner Hildebrand

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details

Stéphane Bézieau

Université de Nantes

FRANCE
View details

Frederic Laumonnier

Team Leader, Research Director

INSERM

FRANCE
View details

Dmitriy Niyazov

Associate Professor

Duke University

UNITED STATES
View details

Renske Oegema

UMC Utrecht

NETHERLANDS
View details

Rami Abou Jamra

University Hospital Leipzig

GERMANY
View details

Jens Meiler

Vanderbilt University

UNITED STATES
View details

Kimberly McDonald

Assistant Professor

University of Mississippi Medical Center

UNITED STATES
View details

Elke Hammer

University Medicine Greifswald

GERMANY
View details

Elke Krueger

Director

University Medicine Greifswald

GERMANY
View details

Julie Hoover-Fong

Professor

Johns Hopkins University

UNITED STATES
View details

Tychele Turner

Assistant Professor

Washington University School of Medicine

UNITED STATES
View details

Frédéric Ebstein

Group Leader

Université de Nantes

FRANCE
View details

Andreas Grabrucker

Lecturer (Assist. Prof)

University of Limerick

IRELAND
View details

Gregory Costain

Hospital for Sick Children

CANADA
View details

Philippe F Backeljauw

University of Cincinnati College of Medicine

UNITED STATES
View details

Antonio Vitobello

Full professor

Université de Bourgogne

FRANCE
View details

Anita Rauch

University of Zurich

SWITZERLAND
View details

Julien Marcoux

CNRS Research Director

Institute of Pharmacology and Structural Biology

FRANCE
View details

Miroslava Hancarova

Charles University

CZECH REPUBLIC
View details